CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Genitope Corporation is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Genitope Corporation
6900 Dumbarton Circle
Phone: 510-284-3000p:510-284-3000 Fremont, CA  94555-3651  United States

This company is no longer actively traded on any major stock exchange.

Business Summary
Genitope Corporation is a development-stage enterprise focused on the research and development of immunotherapies for the treatment of cancer. Until the recent suspension of the development program, the Company's lead product candidate was MyVax personalized immunotherapy (MyVax), indicated for follicular B-cell non-Hodgkin’s Lymphoma (NHL). Genitope has also been developing a panel of monoclonal antibodies that potentially represents an additional , personalized approach for treating NHL. The monoclonal antibodies might reduce or eliminate the need for chemotherapy in the early treatment of NHL. As of December 31, 2007, the Company is evaluating its strategic alternatives with respect to all aspects of its business.
(Source: 10-K)

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
3/31/200812/31/2007YesYesYes--

Industries
SIC Code Description
2836 Biological products, except diagnostic substances

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Chairman of the Board, President, Chief Executive Officer, Interim CFO & Principal Financial Office Dan W.Denney 59 4/28/2008 8/1/1996
Director Gordon D.Denney 56 11/1/1996 11/1/1996
Director GregoryEnnis 47 11/1/1996 11/1/1996
Director William A.Hasler 73 8/1/2000 8/1/2000
Director KentMcGaughy 41 6/1/2008 6/1/2008

Business Names
Business Name
Genitope Corporation
GTOPQ

General Information
Outstanding Shares: 42,984,226 (As of 4/30/2008)
Shareholders: 208
Stock Exchange: OTC
Federal Tax Id: 770436313


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, July 22, 2023